Comparative Evaluation of Modified Vaccinia Ankara as a Surrogate Virus for Disinfectant Efficacy Testing Against AIV, FMDV, and ASFV
Viruses · 23.08.2025 · 17 (9) · 1156
DOI: 10.3390/v17091156 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Viruses, online erschienen am 23.08.2025. Verfasst von Sok Song und 10 weiteren Autor:innen. Beteiligte Einrichtung: Veterinary Drugs & Biologics Division, Animal and Plant Quarantine Agency, Gimcheon 39660, Republic of Korea. Hauptthemen laut MEDLINE: Disinfectants, Vaccinia virus, Foot-and-Mouth Disease Virus, African Swine Fever Virus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Animal and Plant Quarantine Agency.
Abstract (Originalsprache)
Surrogate viruses provide a safe and scalable alternative for evaluating disinfectant efficacy when access to high-risk pathogens is restricted. This study evaluated the potential of Modified Vaccinia Ankara (MVA) virus, which can be handled under BSL-1/2 conditions, as a surrogate for avian influenza virus (AIV), foot-and-mouth disease virus (FMDV), and African swine fever virus (ASFV). A total of 64 commercially available disinfectants—classified into four major chemical groups: quaternary ammonium compounds, oxidizing agents, PPMS-based formulations, and organic acids—were tested in suspension assays using a ≥4 log reduction as the efficacy criterion. MVA showed the strongest predictive performance for FMDV (r = 0.671, AUC = 0.83), supporting its use for both binary classification and approximate quantitative prediction. Although its correlation with ASFV was weaker (r = 0.175), the classification performance remained moderate (AUC = 0.78), indicating conditional applicability. While MVA exhibited no meaningful correlation with AIV, its higher chemical resistance meant that disinfectants effective against MVA were consistently effective against AIV. These results support the use of MVA as a conservative exclusion tool for fragile viruses. Overall, the findings demonstrate that MVA can serve as a practical surrogate virus for disinfectant efficacy testing against FMDV, ASFV, and AIV, with application strategies tailored to each virus’s characteristics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Veterinary Drugs & Biologics Division, Animal and Plant Quarantine Agency, Gimcheon 39660, Republic of Korea.
- Institute for Veterinary Biomedical Science, College of Veterinary Medicine, Kyungpook National University, Daegu 41566, Republic of Korea.
ORCID-Profile: Sok Song, Wooseog Jeong, Choi-Kyu Park
Förderung
- Animal and Plant Quarantine Agency
Zitieren
APA
Song, S., Kim, S. J., Shin, K. S., Park, S. H., Joo, Y. Y., Han, B., Lee, C. Y., Park, G. W., Ku, H. O., Jeong, W., & Park, C. K. (2025). Comparative Evaluation of Modified Vaccinia Ankara as a Surrogate Virus for Disinfectant Efficacy Testing Against AIV, FMDV, and ASFV. Viruses, 17(9), 1156. https://doi.org/10.3390/v17091156
Vancouver
Song S, Kim SJ, Shin KS, Park SH, Joo YY, Han B, et al. Comparative Evaluation of Modified Vaccinia Ankara as a Surrogate Virus for Disinfectant Efficacy Testing Against AIV, FMDV, and ASFV. Viruses. 2025;17(9):1156. doi:10.3390/v17091156
BibTeX
@article{Song2025,
author = {Song, Sok and Kim, Su-Jeong and Shin, Kyu-Sik and Park, So-Hee and Joo, Yong Yi and Han, Bokhee and Lee, Cho-Yeon and Park, Gong-Woo and Ku, Hyun-Ok and Jeong, Wooseog and Park, Choi-Kyu},
title = {Comparative Evaluation of Modified Vaccinia Ankara as a Surrogate Virus for Disinfectant Efficacy Testing Against AIV, FMDV, and ASFV},
journal = {Viruses},
year = {2025},
volume = {17},
number = {9},
pages = {1156},
doi = {10.3390/v17091156}
}
EUVIMED